Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as potentially useful for the treatment of epilepsy, schizophrenia, autism, cancer, mood disorder, sepsis, Alzheimer’s disease and vascular disorders, among others.
Huawu Biopharmaceutical Technology (Hubei) Co. Ltd. has divulged new viral replication inhibitors potentially useful for the treatment of dengue and yellow fever virus infections.
Work at Khartis Therapeutics Inc. has led to the discovery of new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors potentially useful for the treatment of thyroid-associated ophthalmopathy (Graves ophthalmopathy), age-related macular degeneration, idiopathic orbital inflammatory disease, cancer and inflammatory disorders.
Renovare Therapeutics Inc. has announced its formal launch from stealth mode with a focus on developing regenerative therapies for musculoskeletal diseases, including osteoarthritis.
Researchers from Syngenta AG and collaborators reported the preclinical characterization of CHNQD-01522, a microtubule-targeting agent designed based on the marine natural product penipanoid C, in hepatocellular carcinoma (HCC) models.
Chinese researchers from Zhejiang Yangli Pharmaceutical Technology Co. Ltd. have presented data on an aldosterone synthase inhibitor, VB-19055. Inhibiting aldosterone synthase (CYP11B2) could lead to a potential treatment for cardiovascular-renal-metabolic disorders.
Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. for the use of Alloy’s Anticlastic ASO platform to accelerate the development of innovative oligonucleotide therapeutics.
Fortitude Biomedicines Inc. has disclosed that its lead program, FORT-202, is a first-in-class T-cell-targeting bispecific antibody for the potential treatment of axial spondyloarthritis. As a bispecific antibody, FORT-202 is designed to address multiple disease-causing pathways and is expected to significantly improve therapeutic efficacy.
Werner syndrome results from biallelic mutations in the WRN gene on chromosome 8, leading to accelerated aging symptoms. Researchers at Sumitomo Pharma Co. Ltd. have reported the development and characterization of WRN-108, a splice-switching antisense oligonucleotide (ASO) designed to induce exon 27 skipping in WRN transcripts carrying the c.3139-1G>C mutation.
RSS
